Toxicology and Drug Development

Author:

Bebenek Ilona1,McMaster Owen1

Affiliation:

1. U.S. Food and Drug Administration, Division of Pharmacology/Toxicology for Infectious Diseases 10903 New Hampshire Ave. Silver Spring MD 20993 USA ilona.bebenek@fda.hhs.gov

Abstract

Drug development is a lengthy, multi-step process designed to characterize the safety and efficacy of drug candidates before being approved for marketing. Progression through the range of clinical trials and ultimately to product approval depends on a series of risk vs. benefit analyses. Risk is addressed, in part, through non-clinical safety assessment. Of particular importance are studies of safety pharmacology, general toxicology, genetic toxicology, carcinogenicity, and developmental and reproductive toxicology. While regulatory guidance documents and guidelines are available to provide recommendations related to non-clinical drug development, decision making must always be based on the best available science. This chapter covers the various types of non-clinical evaluations focusing on the overall goal of the studies, sources of regulatory recommendations, timing of submission, and utility of the data. Additional details are provided to familiarize the reader with various aspects of regulatory decision making.

Publisher

The Royal Society of Chemistry

Reference26 articles.

1. Drug Development 101: A Primer

2. Harmonised Tripartite Guideline S7A,2000

3. Harmonised Tripartite Guideline S7B,2005

4. Harmonised Tripartite Guideline M3(R2),2009

5. Harmonised Tripartite Guideline S2(R1),2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3